Search Results
Your search for Matthew Stenger matches 7475 pages
Showing 2551 - 2600First-Line Atezolizumab Improves Overall Survival vs Chemotherapy in Certain Patients With Metastatic NSCLC
As reported in The New England Journal of Medicine by Roy S. Herbst, MD, PhD, of Yale School of Medicine, and colleagues, the phase III IMpower110 trial has shown significantly prolonged overall survival with first-line atezolizumab vs platinum-based chemotherapy in metastatic non–small cell lung...
Addition of Abemaciclib to Endocrine Therapy Improves Invasive Disease–Free Survival in High-Risk Early Breast Cancer
As reported in the Journal of Clinical Oncology by Stephen R.D. Johnston, MD, PhD, of the Royal Marsden NHS Foundation Trust, London, and colleagues, an interim analysis in the phase III monarchE trial has shown that adjuvant abemaciclib plus endocrine therapy significantly improved invasive...
Venetoclax in Combination Therapy for Untreated Acute Myeloid Leukemia
On October 16, 2020, venetoclax was granted regular approval for use in combination with azacitidine, decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults aged 75 years or older or those with comorbidities precluding intensive induction...
Pembrolizumab in Adult and Pediatric Classical Hodgkin Lymphoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 14, 2020, the approval of pembrolizumab was...
Reconstruction Implant Surface Texture and Risk of Breast Cancer Recurrence
In a Korean single-institution cohort study reported in JAMA Surgery, Lee et al found that the use of textured surface implants in breast reconstruction following mastectomy for breast cancer was associated with poorer disease-free survival. Study Details The study involved data from 650 women...
Adoption of Hypofractionated Radiation Therapy After Change in Prostate Cancer Clinical Pathway
In a study reported in JCO Oncology Practice, Schad et al found that modifying the prostate cancer clinical pathway in an integrated oncology network to designate moderately hypofractionated external-beam radiotherapy (mHF-EBRT) as the recommended curative EBRT monotherapy in low- and...
Once-Weekly Selinexor Plus Bortezomib/Dexamethasone vs Twice-Weekly Bortezomib/Dexamethasone in Previously Treated Patients With Multiple Myeloma
As reported in The Lancet by Grosicki et al, the phase III BOSTON trial has shown significantly prolonged progression-free survival with once-weekly selinexor plus bortezomib/dexamethasone vs twice-weekly bortezomib/dexamethasone in previously treated patients with multiple myeloma. Study Details...
First-Line Lorlatinib vs Crizotinib in Advanced ALK-Positive NSCLC
As reported in The New England Journal of Medicine by Alice T. Shaw, MD, PhD, and colleagues, an interim analysis of the phase III CROWN trial has shown that first-line lorlatinib significantly improved progression-free survival and intracranial response rate vs crizotinib in patients with advanced ...
Effect of Anterior Approach vs Conventional Hepatectomy in Resection of Colorectal Liver Metastases on Intraoperative Tumor Cell Dissemination
In a German single-institution study reported in JAMA Surgery, Rahbari et al found that the anterior approach to the resection of colorectal liver metastases was not associated with a reduction in the detection of intraoperative circulating tumor cells vs conventional hepatectomy. As stated by the...
Pembrolizumab Plus Bevacizumab and Oral Metronomic Cyclophosphamide for Recurrent Ovarian Cancer
In a single-institution phase II trial reported in JAMA Oncology, Zsiros et al found that the combination of pembrolizumab with bevacizumab and oral metronomic cyclophosphamide produced objective response in approximately half of women with recurrent ovarian cancer taking part in the study....
Association of FDG Uptake According to Deauville Criteria With Survival Outcomes in Newly Diagnosed Multiple Myeloma
In an analysis reported in the Journal of Clinical Oncology, Zamagni et al found that fluorodeoxyglucose F-18 (FDG) uptake of less than 4 on the Deauville scale in bone marrow and focal lesions on pre–maintenance therapy FDG positron-emission tomography/computed tomography (PET/CT) scans was...
Self-Reported Financial Distress Among Older Adults With Cancer Prior to Initiating Therapy
In a single-institution study reported in JCO Oncology Practice, Smith Giri, MD, MHS, and colleagues found that 27% of patients with cancer aged 60 or older reported financial distress in response to a query prior to starting systemic therapy. Numerous demographic and geriatric assessment...
Addition of Ablative Therapy to Transarterial Chemoembolization in Nonmetastatic Unresectable Hepatocellular Carcinoma
In a single-institution cohort study reported in JAMA Network Open, English et al found that the addition of ablative therapy to transarterial chemoembolization improved freedom from local disease progression and overall survival in patients with nonmetastatic unresectable hepatocellular ...
Effects of Stopping Tyrosine Kinase Inhibitor Treatment for Chronic Myeloid Leukemia
In a study (Life After Stopping TKIs; LAST) reported in JAMA Oncology, Atallah et al found that stopping tyrosine kinase inhibitor (TKI) therapy in patients with controlled chronic myeloid leukemia (CML) was associated with maintenance of major molecular response and achievement of treatment-free...
Researchers Develop Prognostic Model to Guide Systemic Therapy for Early-Stage HER2-Positive Breast Cancer
As reported in The Lancet Oncology, Prat et al have developed a prognostic risk score model—HER2DX—that can be used to identify patients with early-stage HER2-positive breast cancer who might be candidates for escalated or de-escalated systemic treatment. As stated by the investigators, “In...
Paclitaxel Plus Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer: Long-Term Follow-up and Genomic Analysis
In a 7-year follow-up of the phase III CALGB 40601/Alliance neoadjuvant trial reported in the Journal of Clinical Oncology, Fernandez-Martinez et al found that paclitaxel combined with trastuzumab/lapatinib was associated with improved survival outcomes vs paclitaxel/trastuzumab in women with...
Addition of Irinotecan to Neoadjuvant Capecitabine Chemoradiation Guided by UGT1A1 Genotype in Locally Advanced Rectal Cancer
In a Chinese phase III trial reported in the Journal of Clinical Oncology, Zhu et al found that the addition of irinotecan to neoadjuvant capecitabine chemoradiation (CapIriRT)—with irinotecan dosing guided by UGT1A1 genotype—followed by capecitabine/irinotecan (XELIRI) significantly improved...
Sentinel Lymph Node Biopsy vs Lymphadenectomy for Staging of Intermediate- and High-Grade Endometrial Cancers
In a Canadian prospective cohort study (SENTOR) reported in JAMA Surgery, Cusimano et al found that sentinel lymph node biopsy showed “acceptable diagnostic accuracy” compared with lymphadenectomy in detecting nodal metastatic disease in patients with intermediate- and high-grade endometrial...
Addition of Venetoclax to Bortezomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma: BELLINI Trial
As reported in The Lancet Oncology by Shaji K. Kumar, MD, and colleagues, the phase III BELLINI trial has shown that the addition of venetoclax to bortezomib/dexamethasone significantly prolonged progression-free survival in patients with relapsed or refractory multiple myeloma but was associated...
Survey Finds Patients With Cancer May Be Less Likely to Enroll in Clinical Trials During the COVID-19 Pandemic
A portion of patients with cancer may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic. According to a report published as a research letter by Mark E. Fleury, PhD, and colleagues in JAMA Oncology, nearly one in five patients with cancer surveyed said the...
Ivosidenib Plus Azacitidine in Newly Diagnosed IDH1-Mutant Acute Myeloid Leukemia
In a phase Ib study reported in the Journal of Clinical Oncology, Courtney D. DiNardo, MD, and colleagues found that the combination of ivosidenib and azacitidine produced a high response rate in patients with newly diagnosed isocitrate dehydrogenase 1 (IDH1)-mutant acute myeloid leukemia...
Can Circulating Tumor Cell Count Guide First-Line Chemotherapy or Endocrine Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer?
In the French phase III STIC CTC trial reported in JAMA Oncology, François-Clément Bidard, MD, PhD, and colleagues found that choice of first-line chemotherapy vs endocrine therapy in hormone receptor (HR)-positive, HER2-negative metastatic breast cancer based on circulating tumor cell count...
Meta-analysis of Outcomes With Gamma Knife Radiosurgery for Uveal Melanoma or Ocular Metastases
In a systematic review and meta-analysis reported in The Lancet Oncology, Parker et al found that Gamma Knife radiosurgery was associated with high local control and tumor regression rates in patients with uveal melanoma or intraocular metastases. As stated by the investigators, “Gamma [K]nife...
Adjuvant Irinotecan/Cisplatin vs Etoposide/Cisplatin for Resected High-Grade Neuroendocrine Carcinoma of the Lung
In a Japanese phase III trial reported in the Journal of Clinical Oncology, Kenmotsu et al found that adjuvant irinotecan/cisplatin did not improve relapse-free survival vs etoposide/cisplatin in patients with completely resected, pathologic stage I–IIIA, high-grade neuroendocrine carcinoma of the...
Surgical Technical Skill and Long-Term Survival After Surgery for Colon Cancer
In a study reported as a research letter in JAMA Oncology, Brajcich et al found that higher-rated surgical technical skill was associated with significantly improved long-term survival in patients undergoing surgery for colon cancer. Study Details In the study, surgeons were recruited from the...
Addition of Indoximod to Taxane Chemotherapy in First-Line Treatment of HER2-Negative Metastatic Breast Cancer
In a phase II trial reported in JAMA Oncology, Mariotti et al found that the addition of the indoleamine 2,3-dioxygenase 1 (IDO1) pathway inhibitor indoximod to a taxane did not improve progression-free survival in first-line treatment of patients with metastatic HER2-negative breast cancer. As...
Comanagement of Induction Therapy for Acute Promyelocytic Leukemia by Experts and Community Practices
In a study reported in JCO Oncology Practice, Anand P. Jillella, MD, and colleagues found that physician education on the main causes of death during induction treatment for acute promyelocytic leukemia (APL)—and comanagement of cases with expert physicians—resulted in a low early mortality rate...
Serial COVID-19 Screening in Asymptomatic Patients Receiving Treatment for Cancer
In a United Arab Emirates single-institution study reported as a research letter in JAMA Oncology, Al-Shamsi et al found a high rate of COVID-19 infection among asymptomatic patients with solid tumors undergoing cancer treatment. Study Details The study included 109 patients receiving treatment for ...
Reduced Breast Cancer Mortality and Risk of Recurrence With Internal Mammary and Medial Supraclavicular Nodal Irradiation in Stage I to III Breast Cancer
As reported in The Lancet Oncology by Philip M. Poortmans, PhD, and colleagues, 15-year outcomes of the phase III EORTC 22922/10925 trial show continued reductions in both breast cancer mortality and recurrence with postsurgery internal mammary and medial supraclavicular (IM-MS) lymph node chain...
rhG-CSF and Decitabine to Reduce Risk of Relapse in Patients With AML After Stem Cell Transplant
In a Chinese phase II trial reported in the Journal of Clinical Oncology, Gao et al found that prophylactic recombinant human granulocyte colony-stimulating factor (rhG-CSF) and minimal-dose decitabine reduced the risk of relapse vs no intervention among patients with high-risk, minimal residual...
Risk of Metachronous Contralateral Testicular Cancer According to Platinum-Based Chemotherapy Exposure
In a Dutch study reported in the Journal of Clinical Oncology, Blok et al found a significant association between an increased number of cycles of platinum-based chemotherapy and a reduced risk of metachronous contralateral testicular cancer. As noted by the investigators, patients with testicular...
Combination of Nivolumab and Ipilimumab for Unresectable Malignant Pleural Mesothelioma
On October 2, 2020, the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) was approved for first-line treatment of adult patients with unresectable malignant pleural mesothelioma.1-3 Supporting Efficacy Data Approval was based on findings in the open-label phase III CheckMate 743 trial...
DANUBE Trial Reports No Survival Benefit With First-Line Durvalumab in Metastatic Urothelial Carcinoma
As reported in The Lancet Oncology by Thomas Powles, MD, of Barts Cancer Institute, Queen Mary University of London, and colleagues, the phase III DANUBE trial showed that durvalumab monotherapy did not prolong overall survival vs standard chemotherapy in previously untreated patients with...
No Biochemical Progression-Free Survival Benefit With Adjuvant vs Salvage Radiotherapy After Radical Prostatectomy for Prostate Cancer
As reported in The Lancet by Christopher C. Parker, MD, of Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, and colleagues, initial findings in the phase III RADICALS-RT trial have shown no biochemical progression-free survival benefit with adjuvant radiotherapy vs a policy of salvage...
Bispecific Anti-CD20/Anti-CD19 CAR T Cells for Patients With Relapsed B-Cell Malignancies
In a single-institution phase I dose-escalation and -expansion trial reported as a letter in Nature Medicine, Shah et al found that treatment with tandem bispecific anti-CD20/anti-CD19 4-1BB–CD3ζ lentiviral (LV20.19) chimeric antigen receptor (CAR) T cells produced high response rates in adult...
Nivolumab Plus Ipilimumab for Metastatic Uveal Melanoma
In a single-institution phase II trial reported in the Journal of Clinical Oncology, Pelster et al found that nivolumab plus ipilimumab produced durable responses and improved survival outcomes in patients with metastatic uveal melanoma. Study Details The trial enrolled 35 patients at The...
Effect of ASH Choosing Wisely Recommendations on Frequency of Surveillance Imaging in Patients With DLBCL
In a retrospective analysis reported in JCO Oncology Practice, Durani et al found that use of surveillance imaging in patients with diffuse large B-cell lymphoma (DLBCL) decreased following publication of the American Society of Hematology (ASH) Choosing Wisely recommendations to limit such imaging ...
Second-Line Pembrolizumab Improves Overall Survival vs Chemotherapy in Patients with Advanced Esophageal Cancer
As reported in the Journal of Clinical Oncology by Takashi Kojima, MD, of the National Cancer Center Hospital East, Kashiwa, Japan, and colleagues, the phase III KEYNOTE-181 trial has shown that second-line pembrolizumab improved overall survival vs the investigator choice of chemotherapy in...
Selpercatinib Shows Activity in RET Fusion–Positive NSCLC and RET-Altered Thyroid Cancer
As reported inThe New England Journal of Medicine by Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues and by Lori J. Wirth, MD, of Massachusetts General Hospital, and colleagues, the phase I/II LIBRETTO-001 trial has shown marked activity of the RET kinase ...
Avelumab Maintenance Therapy Improves Overall Survival in Advanced or Metastatic Urothelial Carcinoma
As reported in The New England Journal of Medicine by Thomas Powles, MD, Barts Cancer Institute, Queen Mary University of London, and colleagues, the phase III JAVELIN Bladder 100 trial found that maintenance treatment with avelumab plus best supportive care significantly improved overall survival...
Olaparib for Patients With Metastatic Breast Cancer and Mutations in Homologous Recombination–Related Genes
In a phase II Translational Breast Cancer Research Consortium (TBCRC) study (TBCRC 048; Olaparib Expanded) reported in the Journal of Clinical Oncology, Nadine M. Tung, MD, and colleagues found that olaparib produced high response rates in patients with metastatic breast cancer and germline PALB2...
Biomarker-Driven Master Protocol to Test Therapies for Previously Treated Patients With Squamous NSCLC
In an article published in The Lancet Oncology, Redman et al described the conduct of and findings from the Lung Cancer Master Protocol (Lung-MAP; SWOG S1400), a completed biomarker-driven master protocol designed to address the need for improved therapies for previously treated patients with...
Effect of a Pay-for-Performance Program on Prescriptions and Spending for Oncology Drugs
In a study reported in the Journal of Clinical Oncology, Justin E. Bekelman, MD, and colleagues found that institution of a national insurer’s pay-for-performance program resulted in a higher rate of prescriptions for evidence-based oncology drug regimens but did not reduce overall health-care...
Extended Follow-up of KEYNOTE-426: First-Line Pembrolizumab/Axitinib vs Sunitinib in Advanced Renal Cell Carcinoma
As reported in The Lancet Oncology by Thomas Powles, MD, PhD, and colleagues, extended follow-up of the phase III KEYNOTE-426 trial shows continued progression-free and overall survival superiority with pembrolizumab/axitinib vs sunitinib in the first-line treatment of advanced renal cell...
Predicting Mortality Outcomes After Intensive Chemotherapy for AML
In a single-institution study reported in the Journal of Clinical Oncology, Palmieri et al found that the Ferrara criteria for determining fitness for intensive chemotherapy—a set of consensus criteria proposed by a panel of experts from the Italian Society of Hematology, Italian Society of...
Potential Factors in Prognostic Discrepancies Among Tests for Recurrence Risk in Patients With Breast Cancer Receiving Endocrine Therapy
The TransATAC study reported by Buus et al in the Journal of Clinical Oncology sought to identify causes of discrepancies among tests for determining the risk of breast cancer recurrence in patients with estrogen receptor–positive, HER2-negative disease receiving endocrine therapy. The...
Multisystem Immune-Related Adverse Events and Disease Outcomes Among Patients With NSCLC Treated With Immunotherapy
In a retrospective cohort study reported in JAMA Oncology, Shankar et al found improved progression-free and overall survival among patients who experienced multisystem immune-related adverse events after anti–PD-1 or anti–PD-L1 immune checkpoint inhibitor therapy for stage III/IV non–small cell...
Response-Based Management of Nivolumab and Ipilimumab Therapy in Metastatic Renal Cell Carcinoma
In the phase II OMNIVORE study reported in the Journal of Clinical Oncology, Rana R. McKay, MD, and colleagues did not find evidence supporting a strategy of discontinuing nivolumab monotherapy in responders and adding ipilimumab in nivolumab nonresponders among patients with metastatic renal cell...
Intermittent Dosing Schedules of RAF/MEK Inhibitor in RAS/RAF-Mutant Solid Tumors and Multiple Myeloma
In a single-center phase I dose-escalation and basket dose-expansion study reported in The Lancet Oncology, Guo et al identified the phase II dose and schedule for the oral RAF/MEK inhibitor CH5126766 in patients with RAS/RAF-mutant cancers. The agent also showed antitumor activity across various...
Outcomes With Second-Line Therapy After Relapse in Patients With Early-Stage, Favorable, Classical Hodgkin Lymphoma
In an analysis of two German Hodgkin Study Group trials reported in the Journal of Clinical Oncology, Bröckelmann et al found that second-line treatment with conventional polychemotherapy resulted in similar second progression–free survival (progression-free survival-2) durations vs high-dose...
